NOMIFENSINE - EFFECT IN PARKINSONIAN-PATIENTS NOT RECEIVING LEVODOPA

被引：21
|
作者：
PARK, DM [1 ]
FINDLEY, LJ [1 ]
HANKS, G [1 ]
SANDLER, M [1 ]
机构：
[1] CHARING CROSS HOSP,DEPT NEUROL,LONDON W6 8RF,ENGLAND
来源：
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY | 1981年 / 44卷 / 04期
关键词：
D O I：
10.1136/jnnp.44.4.352
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：352 / 354
页数：3
相关论文
共 50 条
  • [31] COMBINATION OF SELEGILINE AND CONTROLLED RELEASE LEVODOPA IN THE TREATMENT OF FLUCTUATIONS OF CLINICAL DISABILITY IN PARKINSONIAN-PATIENTS
    CHOUZA, C
    ALJANATI, R
    SCARAMELLI, A
    DEMEDINA, O
    CAAMANO, JL
    BUZO, R
    FERNANDEZ, A
    ROMERO, S
    ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 : 127 - 137
  • [32] DIGITAL ANALYSIS OF THE EFFECTS OF LEVODOPA TREATMENT ON THE VISUAL EVOKED-RESPONSE IN PARKINSONIAN-PATIENTS
    YAAR, I
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1979, 15 (03): : 296 - 296
  • [33] INFLUENCE OF MEAL INGESTION TIME ON PHARMACOKINETICS OF ORALLY-ADMINISTERED LEVODOPA IN PARKINSONIAN-PATIENTS
    BARUZZI, A
    CONTIN, M
    RIVA, R
    PROCACCIANTI, G
    ALBANI, F
    TONELLO, C
    ZONI, E
    MARTINELLI, P
    CLINICAL NEUROPHARMACOLOGY, 1987, 10 (06) : 527 - 537
  • [34] A WALKING AID FOR PARKINSONIAN-PATIENTS
    PEARCE, JMS
    LANCET, 1993, 342 (8862): : 62 - 62
  • [35] THE PHARMACOKINETICS OF LISURIDE IN PARKINSONIAN-PATIENTS
    BURNS, RS
    GOPINATHAN, G
    HUMPEL, M
    DOROW, R
    CALNE, DB
    NEUROLOGY, 1981, 31 (04) : 49 - 50
  • [36] PHARMACOKINETICS OF APOMORPHINE IN PARKINSONIAN-PATIENTS
    NICOLLE, E
    POLLAK, P
    SERREDEBEAUVAIS, FS
    RICHARD, P
    GERVASON, CL
    BROUSSOLLE, E
    GAVEND, M
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1993, 7 (05) : 245 - 252
  • [37] PHARMACOTHERAPY FOR DEPRESSED PARKINSONIAN-PATIENTS
    AYD, FJ
    PSYCHIATRIC ANNALS, 1984, 14 (09) : 689 - 691
  • [38] ATTENTION DISTURBANCES IN PARKINSONIAN-PATIENTS
    DANILOVA, DP
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 1980, 80 (05): : 694 - 696
  • [39] DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF LEVODOPA .2. BIOAVAILABILITY OF MARKETED LEVODOPA PREPARATIONS IN DOGS AND PARKINSONIAN-PATIENTS
    SASAHARA, K
    NITANAI, T
    HABARA, T
    MORIOKA, T
    NAKAJIMA, E
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1980, 69 (03) : 261 - 265
  • [40] VESTIBULAR DISTURBANCES IN PARKINSONIAN-PATIENTS
    HENZI, S
    STANGA, Z
    LUDIN, HP
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1990, 120 (36) : 1297 - 1303
12345